Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Amy Feldman - Italy's $10 Billion Pharma Family Makes A U.S. Power Move
Italy's $10 Billion Pharma Family Makes A U.S. Power Move
Forbes

or more than 100 years, the billionaire Angelini family had been content to run a largely European business empire from their headquarters in Rome: pharmaceuticals like the Italian equivalent of Tylenol and the antidepressant trazodone, as well as…

globenewswire.com - Vistin Pharma ASA - Vistin Pharma ASA: Second quarter and YTD 2026 financial results
Vistin Pharma ASA: Second quarter and YTD 2026 financial results
GlobeNewswire

Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026. Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 2025. Sales volume increased by 8%, offset by a…

thestandard.com.hk - Gloria Leung - Hang Seng climbs nearly 1 percent as pharma and gold stocks surge
Hang Seng climbs nearly 1 percent as pharma and gold stocks surge
The Standard

Hong Kong stocks closed higher on Thursday, broadly boosted by a surge in pharmaceutical and gold shares, while tech heavyweights posted mixed results. SCROLL TO CONTINUE WITH CONTENT The benchmark Hang Seng Index rose 231 points, or 0.91 percent…

thestandard.com.hk - The Standard 英文虎報 - HSI rose 291 points by midday as pharma and commodity shares rally, Kuaishou fell 9.74pc
HSI rose 291 points by midday as pharma and commodity shares rally, Kuaishou fell 9.74pc
The Standard

Hong Kong stocks sustained their upward momentum at noon on Thursday as biopharmaceutical and commodity shares gained further. SCROLL TO CONTINUE WITH CONTENT The benchmark Hang Seng Index rose 291 points, or 1.14 percent, to 25,786 points…

fool.com - Motley Fool Transcribing - ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, Aug. 13, 2026 at 4:30 p.m. ET IR representative - Monique Allaire President and CEO - Donn Casale Chief Financial Officer - Kathy Scott Net Product Revenue -- $26.2 million, primarily driven by sales of neffy in the United States. Total…

seekingalpha.com - Edmund Ingham - Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS)
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS)
Seeking Alpha

Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S…

fool.com - Brendan Coffey - In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
The Motley Fool

The iShares U.S. Pharmaceuticals ETF (IHE -2.26%) and VanEck Biotech ETF (BBH -2.83%) offer targeted exposure to healthcare, with one focusing on established pharmaceutical giants and the other on high-growth genetic research firms. Both funds…

fool.com - Motley Fool Transcribing - Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, Aug. 13, 2026 at 8 a.m. ET Vice President of Investor Relations - Chad Fugure President and Chief Executive Officer - Jan Mikkelsen Chief Financial Officer - Scott Smith Chief Business Officer - Sherrie Glass Executive Vice President and…

fool.com - Andy Gould - IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?
IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?
The Motley Fool

Comparing the iShares U.S. Pharmaceuticals ETF (IHE +2.71%) to the State Street SPDR S&P Biotech ETF (XBI +5.90%) illustrates a familiar healthcare trade-off: the relative stability of massive pharmaceutical conglomerates versus the high-volatility…

thehindu.com - The Hindu Bureau - Pulse Pharma gets DCGI nod for nano-carrier entrapped Vitamin D3 oral dispersion
Pulse Pharma gets DCGI nod for nano-carrier entrapped Vitamin D3 oral dispersion
The Hindu

Pulse Pharmaceuticals has received approval for its nano-carrier entrapped Vitamin D3 oral dispersion from the Drugs Controller General of India (DCGI). The approval transforms advanced nano pharmaceutical research into a regulated, patient-ready…

thehindubusinessline.com - Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical on two insulin analogues
Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical on two insulin analogues
BusinessLine

Mankind Pharma has inked an exclusive in-licensing and marketing agreement with China 's Chongqing Chenan Biopharmaceutical Co Ltd, to commercialise two insulin analogues - Insulin Degludec and Insulin Degludec + Aspart Combination, in India. The…

forbes.com - Danielle Chemtob - Forbes Daily: Moderna Stock Surges On Landmark Cancer Vaccine Trial
Forbes Daily: Moderna Stock Surges On Landmark Cancer Vaccine Trial
Forbes

Moderna had its best trading day ever as the company reported positive results from a landmark cancer vaccine trial. The biotech giant's stock skyrocketed 177% Wednesday after Moderna and Merck reported that their vaccine helped reduce the…

digitaljournal.com - AFP - Walmart reports mixed results as gas prices drag on US sales growth
Walmart reports mixed results as gas prices drag on US sales growth
Digital Journal

Walmart reported mixed results Thursday, topping analyst estimates but experiencing slower US sales growth as consumers contended with lofty gasoline prices due to the US-Iran war. The giant US retailer steered much of the benefit from US tariff…

davidborish.com - The Algorithm Inside Moderna's Cancer Vaccine, and the Pharma AI Race It Reframes
The Algorithm Inside Moderna's Cancer Vaccine, and the Pharma AI Race It Reframes
David Borish

On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine met the main goal of a large late-stage trial in melanoma. The INTerpath-001 study enrolled 1,137 patients whose cutaneous melanoma had been surgically…

forbes.com - Grace Chung - Why International Banking Hub Switzerland Is Also A Billionaire Haven
Why International Banking Hub Switzerland Is Also A Billionaire Haven
Forbes

S witzerland has long been a bastion of finance and fortune making, drawing investors and corporations from around the globe who are attracted to the Alpine country's political stability, economic strength—and attractive tax rates. In fact…

Receive a Daily briefing on Pharma Industry News

Get Started